Literature DB >> 27838900

ROS mediates interferon gamma induced phosphorylation of Src, through the Raf/ERK pathway, in MCF-7 human breast cancer cell line.

Kazem Zibara1,2, Asad Zeidan3, Hassan Bjeije1, Nouhad Kassem1, Bassam Badran4, Nabil El-Zein5,6.   

Abstract

Interferon gamma (IFN-ɣ) is a pleiotropic cytokine which plays dual contrasting roles in cancer. Although IFN-ɣ has been clinically used to treat various malignancies, it was recently shown to have protumorigenic activities. Reactive oxygen species (ROS) are overproduced in cancer cells, mainly due to NADPH oxidase activity, which results into several changes in signaling pathways. In this study, we examined IFN-ɣ effect on the phosphorylation levels of key signaling proteins, through ROS production, in the human breast cancer cell line MCF-7. After treatment by IFN-ɣ, results showed a significant increase in the phosphorylation of STAT1, Src, raf, AKT, ERK1/2 and p38 signaling molecules, in a time specific manner. Src and Raf were found to be involved in early stages of IFN-ɣ signaling since their phosphorylation increased very rapidly. Selective inhibition of Src-family kinases resulted in an immediate significant decrease in the phosphorylation status of Raf and ERK1/2, but not p38 and AKT. On the other hand, IFN-ɣ resulted in ROS generation, through H2O2 production, whereas pre-treatment with the ROS inhibitor NAC caused ROS inhibition and a significant decrease in the phosphorylation levels of AKT, ERK1/2, p38 and STAT1. Moreover, pretreatment with a selective NOX1 inhibitor resulted in a significant decrease of AKT phosphorylation. Finally, no direct relationship was found between ROS production and calcium mobilization. In summary, IFN-ɣ signaling in MCF-7 cell line is ROS-dependent and follows the Src/Raf/ERK pathway whereas its signaling through the AKT pathway is highly dependent on NOX1.

Entities:  

Keywords:  AKT; Cancer; ERK1/2; IFN-ɣ; MCF-7; NOX; ROS; Raf; STAT1; Signal transduction; Src; p38

Year:  2016        PMID: 27838900      PMCID: PMC5362574          DOI: 10.1007/s12079-016-0362-6

Source DB:  PubMed          Journal:  J Cell Commun Signal        ISSN: 1873-9601            Impact factor:   5.782


  29 in total

Review 1.  Mechanisms of type-I- and type-II-interferon-mediated signalling.

Authors:  Leonidas C Platanias
Journal:  Nat Rev Immunol       Date:  2005-05       Impact factor: 53.106

2.  A role for the cyclin-dependent kinase inhibitor p21 in the G1 cell cycle arrest mediated by the type I interferons.

Authors:  P S Subramaniam; H M Johnson
Journal:  J Interferon Cytokine Res       Date:  1997-01       Impact factor: 2.607

3.  Interferon-gamma activates transcription of NADPH oxidase 1 gene and upregulates production of superoxide anion by human large intestinal epithelial cells.

Authors:  Yuki Kuwano; Tsukasa Kawahara; Hironori Yamamoto; Shigetada Teshima-Kondo; Kumiko Tominaga; Kiyoshi Masuda; Kyoichi Kishi; Kyoko Morita; Kazuhito Rokutan
Journal:  Am J Physiol Cell Physiol       Date:  2005-09-14       Impact factor: 4.249

Review 4.  Oxygen and nitrogen are pro-carcinogens. Damage to DNA by reactive oxygen, chlorine and nitrogen species: measurement, mechanism and the effects of nutrition.

Authors:  B Halliwell
Journal:  Mutat Res       Date:  1999-07-15       Impact factor: 2.433

5.  A phosphorylation-acetylation switch regulates STAT1 signaling.

Authors:  Oliver H Krämer; Shirley K Knauer; Georg Greiner; Enrico Jandt; Sigrid Reichardt; Karl-Heinz Gührs; Roland H Stauber; Frank D Böhmer; Thorsten Heinzel
Journal:  Genes Dev       Date:  2009-01-15       Impact factor: 11.361

6.  Implications of an antiparallel dimeric structure of nonphosphorylated STAT1 for the activation-inactivation cycle.

Authors:  Minghao Zhong; Melissa A Henriksen; Kenji Takeuchi; Olaf Schaefer; Bin Liu; Johanna ten Hoeve; Zhiyong Ren; Xiang Mao; Xiaomin Chen; Ke Shuai; James E Darnell
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-07       Impact factor: 11.205

7.  Three-dimensional structure of recombinant human interferon-gamma.

Authors:  S E Ealick; W J Cook; S Vijay-Kumar; M Carson; T L Nagabhushan; P P Trotta; C E Bugg
Journal:  Science       Date:  1991-05-03       Impact factor: 47.728

Review 8.  Tumor intracellular redox status and drug resistance--serendipity or a causal relationship?

Authors:  Shazib Pervaiz; Marie-Veronique Clement
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

9.  Type I IFNs downregulate myeloid cell IFN-γ receptor by inducing recruitment of an early growth response 3/NGFI-A binding protein 1 complex that silences ifngr1 transcription.

Authors:  Staci J Kearney; Christine Delgado; Emily M Eshleman; Krista K Hill; Brian P O'Connor; Laurel L Lenz
Journal:  J Immunol       Date:  2013-08-09       Impact factor: 5.422

Review 10.  Signal transduction by reactive oxygen species.

Authors:  Toren Finkel
Journal:  J Cell Biol       Date:  2011-07-11       Impact factor: 10.539

View more
  11 in total

1.  Sex differences in the acute and subchronic lung inflammatory responses of mice to nickel nanoparticles.

Authors:  Dorothy J You; Ho Young Lee; Alexia J Taylor-Just; Keith E Linder; James C Bonner
Journal:  Nanotoxicology       Date:  2020-08-19       Impact factor: 5.913

Review 2.  Paradoxical roles of dual oxidases in cancer biology.

Authors:  Andrew C Little; Arvis Sulovari; Karamatullah Danyal; David E Heppner; David J Seward; Albert van der Vliet
Journal:  Free Radic Biol Med       Date:  2017-05-31       Impact factor: 7.376

3.  Interferon Potentiates Toll-Like Receptor-Induced Prostaglandin D2 Production through Positive Feedback Regulation between Signal Transducer and Activators of Transcription 1 and Reactive Oxygen Species.

Authors:  Ji-Yun Kim; Go-Eun Choi; Hyun Ju Yoo; Hun Sik Kim
Journal:  Front Immunol       Date:  2017-12-04       Impact factor: 7.561

Review 4.  Cellular Mechanisms of Circulating Tumor Cells During Breast Cancer Metastasis.

Authors:  Han-A Park; Spenser R Brown; Yonghyun Kim
Journal:  Int J Mol Sci       Date:  2020-07-17       Impact factor: 5.923

5.  EGFR signaling suppresses type 1 cytokine-induced T-cell attracting chemokine secretion in head and neck cancer.

Authors:  Wenbo Ma; Fernando Concha-Benavente; Saskia J A M Santegoets; Marij J P Welters; Ilina Ehsan; Robert L Ferris; Sjoerd H van der Burg
Journal:  PLoS One       Date:  2018-09-07       Impact factor: 3.240

6.  Obesity-induced MBD2_v2 expression promotes tumor-initiating triple-negative breast cancer stem cells.

Authors:  Emily A Teslow; Cristina Mitrea; Bin Bao; Ramzi M Mohammad; Lisa A Polin; Greg Dyson; Kristen S Purrington; Aliccia Bollig-Fischer
Journal:  Mol Oncol       Date:  2019-03-01       Impact factor: 6.603

7.  Distinct Protein Expression Networks are Activated in Microglia Cells after Stimulation with IFN-γ and IL-4.

Authors:  Daniele Vergara; Annamaria Nigro; Alessandro Romano; Stefania De Domenico; Marina Damato; Julien Franck; Chiara Coricciati; Maxence Wistorski; Tristan Cardon; Isabelle Fournier; Angelo Quattrini; Michel Salzet; Roberto Furlan; Michele Maffia
Journal:  Cells       Date:  2019-06-12       Impact factor: 6.600

8.  Protein disulfide isomerase A1 regulates breast cancer cell immunorecognition in a manner dependent on redox state.

Authors:  Rashed Alhammad; Sasiprapa Khunchai; Nopprarat Tongmuang; Thawornchai Limjindaporn; Pa-Thai Yenchitsomanus; Luciano Mutti; Marija Krstic-Demonacos; Constantinos Demonacos
Journal:  Oncol Rep       Date:  2020-10-20       Impact factor: 3.906

Review 9.  Infection by High-Risk Human Papillomaviruses, Epithelial-to-Mesenchymal Transition and Squamous Pre-Malignant or Malignant Lesions of the Uterine Cervix: A Series of Chained Events?

Authors:  Giovanni Barillari; Roberto Bei; Vittorio Manzari; Andrea Modesti
Journal:  Int J Mol Sci       Date:  2021-12-17       Impact factor: 5.923

10.  Overexpression of Reactive Oxygen Species Modulator 1 Predicts Unfavorable Clinical Outcome in EGFR-Mutant Lung Adenocarcinomas Treated With Targeted Therapy.

Authors:  Won Gun Kwack; Ji-Youn Sung; Seung Hyeun Lee
Journal:  Front Oncol       Date:  2021-12-09       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.